P450 oxidoreductase deficiency: A new form of congenital adrenal hyperplasia

Current Opinion in Pediatrics

Volumn 18, Issue 4, 2006, Pages 435-441

  Flück, Christa E ^a   Miller, Walter L ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antley Bixler syndrome; Congenital adrenal hyperplasia; Fibroblast growth factor receptor 2; P450 oxidoreductase; Steroidogenesis

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 OXIDOREDUCTASE; CYTOCHROME P450C17; FIBROBLAST GROWTH FACTOR RECEPTOR 2; STEROID; STEROID 21 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ANTLEY BIXLER SYNDROME; AUTOSOMAL RECESSIVE DISORDER; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CYTOCHROME P450 OXIDOREDUCTASE DEFICIENCY; DISEASE SEVERITY; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IN VITRO STUDY; MISSENSE MUTATION; OSSIFICATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; STEROID 17ALPHA MONOOXYGENASE DEFICIENCY; STEROID 21 MONOOXYGENASE DEFICIENCY; STEROIDOGENESIS;

ADRENAL HYPERPLASIA, CONGENITAL; BONE DISEASES, DEVELOPMENTAL; BONE DISEASES, ENDOCRINE; BONE DISEASES, METABOLIC; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; OXIDOREDUCTASES; PHENOTYPE;

EID: 33747495541     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000236395.71956.5c     Document Type: Review

References (70)

1. Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988; 9:295-318.
2. Peterson RE, Imperato-McGinley J, Gautier T, Shackleton CHL. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 1985; 313:1182-1191.
3. Miller WL. Congenital adrenal hyperplasia. N Engl J Med 1986; 314:1321-1322.
4. Malunowicz E, Romer TE, Szarras-Czapnik M, et al. Combined deficiency of 17α-hydroxylase and 21-hydroxylase in an 8 years old girl. Endokrynol Pol 1987; 38:117-124.
5. Augarten A, Pariente C, Gazit E, et al. Ambiguous genitalia due to partial activity of cytochromes P450c17 and P450c21. J Steroid Biochem Mol Biol 1992; 41:37-41.
6. Leiberman E, Hershkovitz E, Lauber-Biason A, et al. Subnormal cortisol response to adrenocorticotropin in isolated partial 17,20-lyase deficiency. J Pediatr Endocrinol Metab 1997; 10:387-390.
7. Adachi M, Tachibana K, Asakura Y, et al. A male patient presenting with major clinical symptomsof glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17α-hydroxylase/17,20-lyase deficiency, but without obvious CYP17 gene mutations. Endocr J 1999; 46:285-292.
8. Reardon W, Smith A, Honour JW, et al. Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000; 37:26-32.
9. Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228-230. The initial report of POR mutations, including the clinical and biochemical characterization of a mild case presenting as PCOS.
10. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749. The only large study of a heterogeneous population, proving the independent segregation of POR and FGFR mutations and providing enzymatic data for all known missense mutations.
11. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128-2135.
12. Shackleton C, Marcos J, Arlt W, Hauffa BP. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet 2004; 129A:105-112.
13. Adachi M, Tachibana K, Asakura Y, et al. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet 2004; 128A:333-339.
14. Wudy SA, Hartmann MF, Draper N, et al. A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency. Endocr Res 2004; 30:957-964.
15. Fukami M, Horikawa R, Nagai T, et al. Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90:414-426. Detailed hormonal data in a large homogeneous population.
16. Fukami M, Hasegawa T, Horikawa R, et al. Cytochrome P450 oxidoreductase deficiency in three patients initially regarded as having 21-hydroxylase deficiency and/or aromatase deficiency: diagnostic value of urine steroid hormone analysis. Pediatr Res 2006; 59:276-280.
17. Miller WL. Minireview: regulation of steroidogenesis by electron transfer. Endocrinology 2005; 146:2544-2550.
18. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004; 36:159-197.
19. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002; 277:6536-6541.
20. Otto DM, Henderson CJ, Carrie D, et al. Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23:6103-6116.
21. Henderson CJ, Otto DM, Carrie D, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486.
22. Wu L, Gu J, Weng Y, et al. Conditional knockout of the mouse NADPH-cytochrome P450 reductase gene. Genesis 2003; 36:177-181.
23. Gu J, Weng Y, Zhang QY, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003; 278:25895-25901.
24. Wu L, Gu J, Cui H, et al. Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: effects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ther 2004; 312:35-43.
25. Wang M, Roberts DL, Paschke R, et al. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94:8411-8416.
26. Shen AL, Kasper CB. Role of acidic residues in the interaction of NADPH-cytochrome P450 oxidoreductase with cytochrome P450 and cytochrome c. J Biol Chem 1995; 270:27475-27480.
27. Estabrook RW, Shet MS, Fisher CW, et al. The interaction of NADPH-P450 reductase with P450: an electrochemical study of the role of the flavin mononucleotide-binding domain. Arch Biochem Biophys 1996; 333:308-315.
28. Hasemann CA, Kurumbail RG, Boddupalli SS, et al. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995; 3:41-62.
29. Fisher CW, Shet MS, Estabrook RW. Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. Methods Enzymol 1996; 272:15-25.
30. Geller DH, Auchus RJ, Mendonca BB, Miller WL. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997; 17:201-205.
31. Auchus RJ, Miller WL. Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999; 13:1169-1182.
32. Kondo S, Sakaki T, Ohkawa H, Inouye K. Electrostatic interaction between cytochrome P450 and NADPH-P450 reductase: comparison of mixed and fused systems consisting of rat cytochrome P450 1A1 and yeast NADPH-P450 reductase. Biochem Biophys Res Commun 1999; 257:273-278.
33. Davydov DR, Kariakin AA, Petushkova NA, Peterson JA. Association of cytochromes P450 with their reductases: opposite sign of the electrostatic interactions in P450BM-3 as compared with the microsomal 2B4 system. Biochemistry 2000; 39:6489-6497.
34. Sevrioukova IF, Li H, Zhang H, et al. Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci U S A 1999; 96:1863-1868.
35. Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975; 11:397-401.
36. DeLozier CD, Antley RM, Williams R, et al. The syndrome of multisynostotic osteodysgenesis with long-bone fractures. Am J Med Genet 1980; 7:391-403.
37. Hassell S, Butler MG. Antley-Bixler syndrome: report of a patient and review of literature. Clin Genet 1994; 46:372-376.
38. Crisponi G, Porcu C, Piu ME. Antley-Bixler syndrome: case report and review of the literature. Clin Dysmorphol 1997; 6:61-68.
39. Jabs EW, Li X, Scott AF, et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet 1994; 8:275-279.
40. Muenke M, Schell U, Hehr A, et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994; 8:269-274.
41. Reardon W, Winter RM, Rutland P, et al. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994; 8:98-103.
42. Gorry MC, Preston RA, White GJ, et al. Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. Hum Mol Genet 1995; 4:1387-1390.
43. Park WJ, Meyers GA, Li X, et al. Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet 1995; 4:1229-1233.
44. Park WJ, Theda C, Maestri NE, et al. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am J Hum Genet 1995; 57:321-328.
45. Schell U, Hehr A, Feldman GJ, et al. Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet 1995; 4:323-328.
46. Wilkie AO, Slaney SF, Oldridge M, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995; 9:165-172.
47. Meyers GA, Day D, Goldberg R, et al. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 1996; 58:491-498.
48. Pulleyn LJ, Reardon W, Wilkes D, et al. Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet 1996; 4:283-291.
49. Gripp KW, Stolle CA, McDonald-McGinn DM, et al. Phenotype of the fibroblast growth factor receptor 2 Ser351Cys mutation: Pfeiffer syndrome type III. Am J Med Genet 1998; 78:356-360.
50. Okajima K, Robinson LK, Hart MA, et al. Ocular anterior chamber dysgenesis in craniosynostosis syndromes with a fibroblast growth factor receptor 2 mutation. Am J Med Genet 1999; 85:160-170.
51. Chun K, Siegel-Bartelt J, Chitayat D, et al. FGFR2 mutation associated with clinical manifestations consistent with Antley-Bixler syndrome. Am J Med Genet 1998; 77:219-224.
52. Roth C, Hinney B, Peter M, et al. Features of Antley-Bixler syndrome in an infant born to a mother with pregnancy luteoma. Eur J Pediatr 2000; 159:189-192.
53. Miller WL. P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab 2004; 15:311-315.
54. Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998; 273:3158-3165.
55. 5. Mol Endocrinol 1999; 13:167-175.
56. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997; 62:133-142.
57. Yanagibashi K, Hall PF. Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 1986; 261:8429-8433.
58. Lin D, Black SM, Nagahama Y, Miller WL. Steroid 17α-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 1993; 132:2498-2506.
59. 5 and by serine phosphorylation of P450c17. J Biol Chem 2005; 280:13265-13271.
60. Pandey AV, Mellon SH, Miller WL. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem 2003; 278: 2837-2844.
61. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995; 92:10619-10623.
62. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84:4677-4694.
63. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15:432-438.
64. Ono T, Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem 1975; 250:1571-1579.
65. Debeljak N, Fink M, Rozman D. Many facets of mammalian lanosterol 14α-demethylase from the evolutionarily conserved cytochrome P450 family CYP51. Arch Biochem Biophys 2003; 409:159-171.
66. Kelley RI, Kratz LE, Glaser RL, et al. Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 2002; 110:95-102.
67. Pursley TJ, Blomquist IK, Abraham J, et al. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336-340.
68. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72:253-256.
69. Cooper MK, Wassif CA, Krakowiak PA, et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003; 33:508-513.
70. Gofflot F, Hars C, Illien F, et al. Molecular mechanisms underlying limb anomalies associated with cholesterol deficiency during gestation: implications of Hedgehog signaling. Hum Mol Genet 2003; 12:1187-1198.